has entered a collaboration with Hungary-based pharmaceutical company to develop new treatments for neuropsychiatric conditions. The agreement focuses on discovering, co-developing and licensing new targets to address these conditions. The gold standard of business intelligence.
The partnership leverages almost two decades of successful collaboration on central nervous system projects. It has already led to the delivery of products such as cariprazine (VRAYLAR/REAGILA) and the development of the investigational drug candidate ABBV-932, aimed at treating bipolar depression and generalised anxiety disorder. VRAYLAR is a prescription therapy designed to work alongside antidepressants in adults, treating major depressive disorder, manic or mixed episodes associated with bipolar I disorder, and schizophrenia.
The new agreement’s terms include preclinical and clinical research and development activities, with costs shared by both parties. Richter will receive a $25m upfront cash payment, with potential additional future payments tied to development, regulatory and commercial milestones. Access the most comprehensive Company Profiles on the market, powered by GlobalData.
Save hours of research. Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles.
However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form The com.
